Skip to main content

Dostarlimab-gxly

(dos-TAR-lih-mab)

This page contains brief information about dostarlimab-gxly and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
Jemperli
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Dostarlimab-gxly is approved to treat:

Dostarlimab-gxly is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Dostarlimab-gxly is also being studied in the treatment of other types of cancer.

More About Dostarlimab-gxly

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

Research Results and Related Resources

Targeted Cancer Therapies

Immune Checkpoint Inhibitors

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Dostarlimab-gxly - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: